The FDA has released three new guidance documents on cell and gene therapy development, covering clinical trial design and ...
T, this time inking a deal worth up to $1.64 billion biobucks with Chinese biotech Pregene Biopharma. | Gilead’s Kite Pharma ...
Ginkgo Bioworks (NYSE: DNA) today announced a collaboration with STRM.BIO and the University of British Columbia (UBC) as part of the Advanced Research Projects Agency for Health's (ARPA-H) ...
Poster presentation title: P53 mutant tumor regression across P53 mutations with AAN-53x, a P53 mRNA delivered with the PEP-NP tumor-targeted peptide (non-lipid) delivery system Presenter: Gilles ...
Kernal has been awarded up to $48M funding to accelerate the development of KR-402, a next-generation in vivo CAR T-cell ...
Award will support development of a single dose in vivo chimeric antigen receptor T cell (CAR-T) therapy to retrain immune cells directly within ...
Nkarta CEO Paul Hastings recently spoke to the importance of the industry's collaborations with Chinese biopharma companies.
I rate AbbVie stock as a Strong Buy, based on its FDA approval of Rinvoq. Read the latest analysis on the stock here.
Bristol Myers Squibb said Friday that it would buy Cambridge startup Orbital Therapeutics for $1.5 billion in cash, the latest move in a brewing race to develop safer and more scalable cell therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback